Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer.

ABSTRACT:

Background and objective

Prostate-specific antigen (PSA) is of limited value as a surrogate marker for overall survival (OS) in prostate cancer (PC). Serum thymidine kinase 1 (sTK1) is an enzyme expressed by actively dividing cells. Our aim was to evaluate the value of sTK1 as prognostic biomarker in metastatic hormone-sensitive PC (mHSPC) and metastatic castration-resistant PC (mCRPC).

Methods

sTK1 was examined in three cohorts: (1) 43 men with de novo mHSPC managed with androgen deprivation monotherapy; (2) 99 patients with mCRPC managed with androgen receptor signaling inhibitors (ARSIs); and (3) 98 patients with mCRPC treated with docetaxel. sTK1 levels were determined at treatment initiation. OS was evaluated using Cox regression analysis.

Key findings and limitation

SUBMITTER: Murtola TJ 

PROVIDER: S-EPMC11547961 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature